Alnylam Ends Revusiran In Phase III, But Was Failure Due To Safety Or Efficacy?

Alnylam’s stock fell more than 40% in after-hours trading following the decision to end development of revusiran based on an imbalance of deaths in the Phase III ENDEAVOR clinical trial, but executives see no read-through to the rest of the company’s RNAi platform.